AbbVie Inc. $ABBV Stock Position Raised by TrueMark Investments LLC

Key Points

• TrueMark Investments LLC raised its AbbVie stake by 17.4% in Q4 to 32,977 shares worth about $7.54M, making AbbVie 1.4% of its portfolio and the company’s 28th largest holding; institutional investors own 70.23% of AbbVie.
• AbbVie beat quarterly expectations (EPS $2.71, revenue $16.62B), set FY2026 guidance of 14.370–14.570 EPS, and announced a $1.73 quarterly dividend (annual $6.92, yield 3.3%).
• Analysts give AbbVie an average rating of "Moderate Buy" with a $253.15 average price target, while the stock trades near $209.46 with a market cap of $370.4B and a P/E of 88.76.

TrueMark Investments LLC lifted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 17.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 32,977 shares of the company's stock after buying an additional 4,878 shares during the quarter. AbbVie comprises 1.4% of TrueMark Investments LLC's investment portfolio, making the stock its 28th largest holding. TrueMark Investments LLC's holdings in AbbVie were worth $7,535,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Diversified Trust Co lifted its position in shares of AbbVie by 23.6% in the third quarter. Diversified Trust Co now owns 57,076 shares of the company's stock worth $13,215,000 after buying an additional 10,891 shares during the last quarter. Permanent Capital Management LP acquired a new position in shares of AbbVie during the 3rd quarter valued at about $720,000. Railway Pension Investments Ltd raised its stake in shares of AbbVie by 33.0% in the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company's stock valued at $197,723,000 after acquiring an additional 211,800 shares in the last quarter. World Investment Advisors raised its stake in shares of AbbVie by 9.4% in the 3rd quarter. World Investment Advisors now owns 113,925 shares of the company's stock valued at $26,378,000 after acquiring an additional 9,811 shares in the last quarter. Finally, Charles Schwab Trust Co lifted its holdings in AbbVie by 93.4% in the 3rd quarter. Charles Schwab Trust Co now owns 32,105 shares of the company's stock worth $7,434,000 after purchasing an additional 15,502 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of recent analyst reports. William Blair reiterated an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research note on Tuesday, January 20th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of AbbVie in a report on Wednesday, January 21st. Sanford C. Bernstein reiterated a "market perform" rating on shares of AbbVie in a research note on Thursday, February 5th. Finally, BMO Capital Markets reiterated an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $253.15.

AbbVie Stock Up 0.0%

Shares of NYSE ABBV opened at $209.46 on Monday. The business's 50 day moving average is $221.96 and its two-hundred day moving average is $224.71. The company has a market cap of $370.37 billion, a P/E ratio of 88.76, a P/E/G ratio of 0.73 and a beta of 0.34. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts' expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie's revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the prior year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie's dividend payout ratio is 293.22%.

Insider Buying and Selling at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.08% of the company's stock.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Company outlook and dividend expectations — Analysts and commentators highlight AbbVie’s strong 2026 guidance and the likelihood of future dividend increases, driven by cash flow from Humira/Imbruvica/oncology and growth in the dermatology portfolio; that narrative supports income investors and dividend yield buyers. AbbVie: Strong 2026 Outlook, Expect Dividend Increases
• Positive Sentiment: Clinical and real‑world data boost dermatology franchise — AbbVie announced new clinical and real‑world evidence for risankizumab (psoriasis/psoriatic arthritis) and upadacitinib (atopic dermatitis), plus Phase‑3 data for vitiligo and alopecia areata to be presented at AAD 2026. Strong safety/efficacy reads can support durable revenue and reduce investor uncertainty around launches. AbbVie to Highlight New Clinical and Real-World Evidence...
• Positive Sentiment: Analyst estimate tweak — Erste Group modestly raised its FY2027 EPS estimate for AbbVie, signaling incremental confidence in earnings power (small change but supportive vs. downside fears). MarketBeat AbbVie Profile
• Neutral Sentiment: Allergan Aesthetics (AbbVie unit) scientific presence — Allergan is presenting multiple evidence‑based posters and product positioning (JUVÉDERM, HA injectables) at AMWC, reinforcing aesthetics growth and brand leadership but with limited immediate revenue impact. Allergan Aesthetics Reinforces Scientific Differentiation...
• Neutral Sentiment: Dividend yield framing for investors — Retail‑focused pieces (The Motley Fool) calculate how many ABBV shares generate targeted dividend income; useful for income investors but not an earnings catalyst. Here's How Many Shares of AbbVie (ABBV) Stock You'd Need...
• Negative Sentiment: Recent price weakness & value debate — Coverage noting recent share‑price declines and questions about valuation may pressure sentiment in the short term; headline focus on near‑term multiple compression can spur selling even as fundamentals are debated. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.